fbpx

PERT Consortium and BTG Form Strategic Partnership

BTG plc (LSE: BTG), the global healthcare company, today announced at
the annual PERT ConsortiumTM Meeting in Nashville, TN, a
strategic partnership with the PERT ConsortiumTM to advance
the science of Pulmonary Embolism (PE) treatment and promote the
implementation of PERTTM programs across the U.S.

In the United States, pulmonary embolism afflicts 500,000–600,000
patients annually1,2 and is either a primary or secondary
cause of death in 150,000–200,000 of these individuals2. In
their new partnership, BTG and the PERT ConsortiumTM are
uniting to address this disease via expanding options for professional
education, expanding clinical research, establishing quality benchmarks
for care of PE, and developing new mobile technologies to convene PERT
teams and improve decision-making.

“With this partnership, we are reaffirming our long-standing commitment
to improving patient care and reducing in-hospital mortality associated
with Pulmonary Embolism,” said BTG Chief Medical Officer, Francis
Facchini. “By partnering with the PERT ConsortiumTM, we hope
to develop new strategies to transform the PE treatment paradigm.”

“We applaud BTG’s commitment to research and their leadership in the
field of PE,” said PERT ConsortiumTM President, Victor
Tapson. “This partnership will expand the body of clinical evidence and
improve multi-disciplinary decision-making for PE patients.”

“PE is a pervasive disease that is under-recognized and undertreated,”
according to Consortium Immediate Past-president Kenneth Rosenfield.
“Our collaboration with BTG will enable the PERT ConsortiumTM
to increase provider and patient awareness about PE, and establish new
benchmarks for high quality care of the patient with this disease.”

About Pulmonary Embolism

Pulmonary
Embolism (PE) is a condition that occurs when a piece of a blood
clot breaks off from a clot in the legs and travels through the
vasculature — getting trapped in the Pulmonary Arteries. When this
happens, the clot blocks blood from getting to some areas of the lungs
to receive oxygen. This may lead to excessive strain on the right side
of the heart, ultimately leading to heart failure and/or cardiovascular
collapse. PEs can be immediately fatal, but if diagnosed and appropriate
therapy started, mortality can be reduced from approximately 30 percent
to less than 10 percent.

About Pulmonary Embolism Response Teams (PERT)

The first PERTTM was created by a multi-disciplinary team of
physicians at Massachusetts General Hospital (MGH) in 2012. Their intent
was to develop the necessary clinical, educational, and research
infrastructure for the advancement of PE care. Since then, the PERTTM
multidisciplinary approach has allowed for the streamlined evaluation of
patients, formulation of comprehensive treatment plans and the rapid
mobilization of resources to provide the highest level of care to those
in need. The PERTTM model has since grown in popularity and
continues to be adopted by institutions across the US and beyond.

About the PERT Consortium

The PERT ConsortiumTM is a not-for-profit 501c3 organization,
whose mission is to serve the general public by undertaking activities
to advance the status of PE care and promote research, enhance quality,
and optimize outcome in the treatment of pulmonary embolism.
Specifically, the Consortium intends to: 1) Promote the adoption of the
PERT model in healthcare institutions across the United States to ensure
the prompt diagnosis and high quality treatment of pulmonary embolism;
2) Expand the current body of scientific literature on the diagnosis and
treatment of pulmonary embolism through the funding of scientific
endeavors; 3) Educate the general public and healthcare professionals
regarding pulmonary embolism diagnosis, treatment, and care. To learn
more about the PERT Consortium™, please visit: pertconsortium.org.

About BTG

BTG is a global healthcare company focused on Interventional Medicine.
Our innovative medical technology helps physicians treat their patients
through minimally invasive procedures. We have a growing portfolio of
products that advance the treatment of cancer, vascular conditions and
severe emphysema. BTG’s Pharmaceuticals business provides products that
help patients overexposed to certain medications or toxins. To learn
more about BTG, please visit: btgplc.com.

Reference materials as the remarks in the press release:

View source version on businesswire.com: https://www.businesswire.com/news/home/20180621005680/en/